A new blood module for continuous renal replacement therapies.
A new blood module for continuous renal replacement therapies has been utilized to perform CVVH in critically ill patients. The features of the new module named (HP300 and manufactured by Medica srl (Medolla, Modena) are the easy installation and transportability to the bedside, the simple and safe management and the continuous measurement of the pre and post filter pressure with automatic calculation of the end-to-end pressure drop inside the filter. The last feature permits to detect early malfunctions of the filter due to fibers clotting or due to the internal coating of the hollow fibers by plasma proteins. In both cases the efficiency of the treatment can be reduced because of a significant reduction of the ultrafiltration rates or a remarkable decay of the membrane permeability and solute sieving coefficients. In many cases this reduction is only detected when important effects on solute removal have already occurred. In our experience, the new module permitted the substitution of the filters when early malfunctions were detected and maximal treatment efficiency was therefore guaranteed over extended periods of time.
Ronco
C
C
Department of Nephrology, St. Bortolo Hospital, Vicenza, Italy.
Fecondini
L
L
Gavioli
L
L
Conz
P
P
Milan
M
M
Dell'Aquila
R
R
Bragantini
L
L
Chiaramonte
S
S
Brendolan
A
A
Crepaldi
C
C
D006440:Hemofiltration / Q000295:instrumentation*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy